- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07330245
Opnåelse af LLDAS5 hos patienter med systemisk lupus erythematosus behandlet med anifrolumab. (DAHLIA)
DAHLIA: Opnåelse af lavt niveau for sygdomsaktivitet med en dosis af kortikosteroider mindre end eller lig med 5 mg (LLDAS5): et real-life studie med anifrolumab på patienter med systemisk lupus erythematosus i Italien
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
DAHLIA study aims to expand real-world evidence on anifrolumab role in clinical practice, specifically evaluating its effectiveness in achieving and maintenance of LLDAS with a dose of corticosteroids less than or equal to 5 mg/day (LLDAS5). Moreover it will provide data on corticosteroid tapering strategies. Additionally, will be also evaluated the Definitions Of Remission In SLE (DORIS) remission during the study period, as well as the depressive symptoms of these patients.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
-
Ancona, Italien, 60126
- Rekruttering
- AOU Ospedali Riuniti di Ancona - Presidio Torrette
-
Bari, Italien, 70124
- Trukket tilbage
- Azienda Ospedaliero-Universitaria Policlinico di Bari
-
Brescia, Italien, 25123
- Rekruttering
- ASST Spedali Civili di Brescia
-
Florence, Italien, 50134
- Rekruttering
- Azienda Ospedaliero-Universitaria Careggi
-
Milan, Italien
- Ikke rekrutterer endnu
- IRCCS Ospedale San Raffaele
-
Milan, Italien, 20122
- Rekruttering
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Italien, 41124
- Ikke rekrutterer endnu
- Policlinico di Modena - AOU di Modena
-
Naples, Italien
- Ikke rekrutterer endnu
- Azienda Ospedaliera Universitaria "Luigi Vanvitelli"
-
Padova, Italien, 35128
- Ikke rekrutterer endnu
- Azienda Ospedaliera di Padova
-
Palermo, Italien, 90127
- Rekruttering
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
-
Pavia, Italien, 27100
- Rekruttering
- Fondazione IRCCS Policlinico San Matteo
-
Pisa, Italien, 56126
- Ikke rekrutterer endnu
- Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara
-
Roma, Italien, 00133
- Ikke rekrutterer endnu
- Policlinico Tor Vergata
-
Roma, Italien, 00161
- Rekruttering
- Policlinico Umberto I - Sapienza Università di Roma
-
Torino, Italien, 10128
- Ikke rekrutterer endnu
- Azienda Ospedaliera Ordine Mauriziano Umberto I
-
Trieste, Italien, 34128
- Rekruttering
- Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara
-
Udine, Italien, 33100
- Rekruttering
- ASU Friuli Centrale - Ospedale Santa Maria della Misericordia di Udine
-
Verona, Italien, 37134
- Rekruttering
- AOUI Verona - Ospedale Borgo Roma
-
-
CA
-
Monserrato, CA, Italien, 09032
- Rekruttering
- Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato
-
-
Ferrara
-
Cona, Ferrara, Italien, 44124
- Rekruttering
- Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna
-
-
Foggia
-
San Giovanni Rotondo, Foggia, Italien
- Rekruttering
- IRCCS Casa Sollievo della Sofferenza
-
-
Milano
-
Rozzano, Milano, Italien, 20089
- Rekruttering
- IRCCS Humanitas Research Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adult patients with Systemic Lupus Erythematous (SLE) according to 2019 EULAR/ACR classification criteria, treated with anifrolumab as per clinical practices.
Beskrivelse
Inclusion Criteria:
- Provided informed consent to participate in the study;
- Aged 18 years or older;
- Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
- Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;
Exclusion Criteria:
- Patients who are at LLDAS5 at the time of study entry;
- Previous exposure to anifrolumab;
- Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy [mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
- Currently participating in any interventional clinical trial with an investigational product;
- Inability to understand and sign the informed consent and to fill in patient questionnaires
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number and percentage of patients achieving LLDAS5
Tidsramme: 52 weeks
|
proportion of patients with LLDAS5 at 52 weeks, defined as: LLDAS5 is defined as follows:
|
52 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number and percentage of patients reaching LLDAS5 at each time point
Tidsramme: week 24, 76 and 104
|
Proportion of patients with LLDAS5, according the following definition: LLDAS5 is defined as follows:
|
week 24, 76 and 104
|
|
Number and percentage of patients achieving a GCS (Glucocorticosterioids) dose reduction
Tidsramme: week 4, 12, 24, 52, 76, 104 vs baseline
|
Number and percentage of patients achieving a GCS dose reduction (to ≤ 5 mg/day; to 0 mg/day) at different timepoints (T1, T2, T3, T4, T5, T6) compared to T0 |
week 4, 12, 24, 52, 76, 104 vs baseline
|
|
Median (range) cumulative dose of GCS
Tidsramme: from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104
|
Median cumulative dose of GCS calculated at each 6 month period following T0 |
from week 0 to week 24; from week 24 to week 52; from week 52 to week 76; from week 76 to week 104
|
|
Mean(SD) change in tender and swollen joint count
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in tender and swollen joint count using Disease Activity Score 28 (DAS28) map at different timepoints compared to baseline (w0). DAS28 ranges from 0 (no-activity) to 10 (high disease activity) |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
mean (SD) change in Power Doppler (PD) Signal Total score
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in Power Doppler (PD) Signal at each time point vs baseline. PD Signal ranges from 0 (low) to 84 (high) |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
mean (SD) change in Synovial Hypertrophy (SH) Total score
Tidsramme: week 4, 12, 24, 52, 76 and 104 vs week 0
|
Mean change in synovial hypertrophy at each time point vs baseline. Synovial hypertrophy ranges from 0 (low) to 84 (high). |
week 4, 12, 24, 52, 76 and 104 vs week 0
|
|
Annualize flaire rate
Tidsramme: week 52 and week 104
|
Annualized flare rate in the first and second years |
week 52 and week 104
|
|
Number and percentage of patients meeting the DORIS clinical remission
Tidsramme: week 12, 24, 52, 76 and 104
|
Number and percentage of patients meeting the DORIS clinical remission definition at each timepoints, according to:
|
week 12, 24, 52, 76 and 104
|
|
Number and percentage of patients with sustained DORIS remission
Tidsramme: week 104
|
Number and percentage of patients with sustained DORIS remission, defined as remaining in remission at or greater than 12 weeks after having met the DORIS definition |
week 104
|
|
Mean (SD) HDRS (Hamilton Depression Rating Scale) total score
Tidsramme: week 12, 24, 52 and 104 vs week 0
|
Change in HDRS total score at different timepoints compared to T0. HDRS ranges from 0 (no depression) to 54 (severe) |
week 12, 24, 52 and 104 vs week 0
|
|
Mean (SD) PROMIS Depression Short Form 8b (Patient-Reported Outcomes Measurement Information System) total score
Tidsramme: week 12, 24, 52 and 104 vs week 0
|
Change in PROMIS Depression Short Form 8b total score at different timepoints compared to week 0 (baseline). PROMIS raw scores ranges from 8 (no depression) to 40 (severe) |
week 12, 24, 52 and 104 vs week 0
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- D3461R00093
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .